BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] slipped around -0.28 points on Wednesday, while shares priced at $4.09 at the close of the session, down -6.41%. BioCryst Pharmaceuticals Inc. stock is now 18.55% up from its year-to-date (YTD) trading value. BCRX Stock saw the intraday high of $4.36 and lowest of $4.085 per share. The company’s 52-week high price is 6.29, which means current price is +158.86% above from all time high which was touched on 05/12/20.
Compared to the average trading volume of 10.40M shares, BCRX reached a trading volume of 6154950 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about BioCryst Pharmaceuticals Inc. [BCRX]?
BTIG Research have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on June 17, 2020. The new note on the price target was released on May 05, 2020, representing the official price target for BioCryst Pharmaceuticals Inc. stock. Previously, the target price had yet another drop from $5 to $4, while BofA/Merrill kept a Buy rating on BCRX stock. On May 24, 2019, analysts decreased their price target for BCRX shares from 16 to 4.50.
The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 0.44, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 14.58. The Price to Book ratio for the last quarter was 204.50, with the Price to Cash per share for the same quarter was set at 0.66.
How has BCRX stock performed recently?
BioCryst Pharmaceuticals Inc. [BCRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.50. With this latest performance, BCRX shares dropped by -17.04% in over the last four-week period, additionally plugging by 28.21% over the last 6 months – not to mention a rise of 13.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 43.93, with the RSI for the last a single of trading hit 39.30, and the three-weeks RSI is set at 48.02 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 4.08, while it was recorded at 4.29 for the last single week of trading, and 3.03 for the last 200 days.
BioCryst Pharmaceuticals Inc. [BCRX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and BioCryst Pharmaceuticals Inc. [BCRX] shares currently have an operating margin of -203.66 and a Gross Margin at +91.60. BioCryst Pharmaceuticals Inc.’s Net Margin is presently recorded at -222.99.
Return on Total Capital for BCRX is now -85.02, given the latest momentum, and Return on Invested Capital for the company is -135.90. Return on Equity for this stock declined to -248.94, with Return on Assets sitting at -67.61. When it comes to the capital structure of this company, BioCryst Pharmaceuticals Inc. [BCRX] has a Total Debt to Total Equity ratio set at 221.30. Additionally, BCRX Total Debt to Total Capital is recorded at 68.88, with Total Debt to Total Assets ending up at 48.30. Long-Term Debt to Equity for the company is recorded at 116.84, with the Long-Term Debt to Total Capital now at 36.37.
Reflecting on the efficiency of the workforce at the company, BioCryst Pharmaceuticals Inc. [BCRX] managed to generate an average of -$777,836 per employee. Receivables Turnover for the company is 3.69 with a Total Asset Turnover recorded at a value of 0.30.BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 1.40.
Earnings analysis for BioCryst Pharmaceuticals Inc. [BCRX]
With the latest financial reports released by the company, BioCryst Pharmaceuticals Inc. posted -0.34/share EPS, while the average EPS was predicted by analysts to be reported at -0.31/share.When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -9.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 19.90%.
Insider trade positions for BioCryst Pharmaceuticals Inc. [BCRX]
There are presently around $536 million, or 72.30% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 13,395,617, which is approximately 10.25% of the company’s market cap and around 0.20% of the total institutional ownership; BAKER BROS. ADVISORS LP, holding 10,946,166 shares of the stock with an approximate value of $47.84 million in BCRX stocks shares; and VANGUARD GROUP INC, currently with $38.33 million in BCRX stock with ownership of nearly 8.009% of the company’s market capitalization.
Positions in BioCryst Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 79 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 21,454,301 shares. Additionally, 66 investors decreased positions by around 41,570,409 shares, while 17 investors held positions by with 59,645,140 shares. The mentioned changes placed institutional holdings at 122,669,850 shares, according to the latest SEC report filing. BCRX stock had 25 new institutional investments in for a total of 6,751,189 shares, while 27 institutional investors sold positions of 11,674,504 shares during the same period.